Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5383_Библиотеки_им_академика_М_И_Перельмана
.pdf
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
be approved by the FDA for pediatric solid tumor and high-risk neuroblastoma[87].
Anti-GD2mAbs work by binding to the end-terminal penta-oligosaccharide of GD2
and following the ADCC or CDC pathways to kill neuroblastoma tumor cells.
Besides ADCC and CMC pathways, mAbs can enhance nonimmune-mediated
effects, such as survival signal blockade and anoikis. Anoikis is the induction of
apoptosis in cells. It occurs when abnormal cells detach from the extracellular
matrix (ECM) and neighboring cells. In a healthy system, anoikis would remove the
unhealthy or abnormal cells, but tumor cells have the ability to escape anoikis by
constitutive activation of focal adhesion kinase (FAK). However, anti-GD2mAbs
will dephosphorylate FAK and inhibit activation of PI3K/Akt pathways, which
allows the drug to induce apoptosis and cause cancer cell death[87].
7.7.3 Challenges with Unituxin
Unituxin can cause serious adverse side reactions because it binds to GD2 expressed in
both benign and malignant tissues. This means neural tissues in the central nervous
system, peripheral nerves, and neuroblastoma can be affected by the drug [79].
Dinutuximab is a toxic regimen that must be infused into patients over a 20-hour
period in a hospital because there is serious risk of intense pain, serious infusion reactions, capillary leak syndrome, and hypotension[41]. This drug can give patients an
increased risk of infection, neurological eye disorders, suppression of bone marrow,
electrolyte abnormalities, and atypical hemolytic uremic syndrome. It is limited for use
in pediatric patients because adults with melanoma who participated in dose-finding,
safety, and tolerability studies experienced severe and possibly irreversible motor neuropathy[41, 79]. However, Unituxin was still approved because of the seriousness of
the disease and the lack of alternative treatment options for high-risk neuroblastoma[79]. Murine anti-GD2mAbs are tolerated in patients and do show antineuroblastoma activity, but the development of HAMA response and hypersensitive reactions
to injections limit how often the drug can be administered[74, 77]. Some patients had
to wait months for the next round of antibody injections to be administered, which
decreased the efficiency and effectiveness of the treatment. HAMA’s increase the clearance of murine mAbs and often cause unwanted allergic reactions and tumor penetration[75]. Murine mAbs have a shorter half-life than human mAbs, and the Fc region
of murine antibodies is less effective at eliciting ADCC and CDC than human antibodies[73, 77]. These limitations have led to advances in genetic engineering that have
allowed for the development of chimeric and humanized anti-GD2mAbs[87].
211
7.7.4 mAbs Binding to Neuroblastoma
The anti-GD2murine antibodies include murine IgG3 (m3F8) and murine IgG2a
(14G2a). Murine 3F8 was the first anti-GD2monoclonal antibody to be tested in
patients with neuroblastoma, and it is the murine IgG3with the highest reported
affinity for GD2with a K
value of 5 nM. Murine 3F8has been shown to kill neuro-
D
blastoma cells by CDC and by lymphocytes, cultured monocytes, and granulocytes.
Murine 3F8 binds to Fc-receptors FcyRII and FcyRIII for neutrophil- and
7 Carbohydrate-Specific Monoclonal Antibody Therapeutics
212
NK-mediated ADCC. The CR3 receptor also plays an important role in cytotoxicity[83, 87]. CDC can be enhanced by naturally occurring complex polysaccharide
β-glucan (BG)[36]. This enhancement increases the adhesion of complement receptors on myeloid cells to natural ligands like iC3b. When m3F8 is combined with the
cytokine GM-CSF, there is a greater than 60% long-term survival rate among pediatric patients with stage-4 high-risk neuroblastoma.
Other murine anti-GD2 antibodies include ME36.1 and 14.G2a, which have lower
affinities to GD2 with K
values of 19 and 77 nM, respectively[83, 89]. While
D
ME36.1was originally obtained as a mouse IgG3, it can be class-switched to IgG2a
and IgG1 variants. Also, ME36.1mostly binds to GD2, but it does have some crossreactivity to GD3, which means that ME36.1 can be a useful antibody for targeting
other tumors, such as melanoma[83]. Preclinical studies showed ME36.1-inhibiting
tumor growth at the inoculation site and in the lymph nodes and lungs.
7.7.5 Chimeric and Humanized Anti-GD2 Antibodies
When creating chimeric versions of the anti-GD2mAbs, the VH and VL domains of
the murine antibody are grafted onto human IgG constant domains. When creating
humanized versions of the anti-GD2mAbs, a fully human monoclonal antibody is
grafted with murine CDR loops and a few structurally significant residues, or a fully
human monoclonal antibody with no murine residues is used[77, 83]. L72, which
is a fully human IgM, was the first nonmurine anti-GD2 antibody. It was produced
using the Epstein–Barr virus (EBV) to transform B lymphocytes from the peripheral
blood lymphocytes of melanoma patients into lymphoblastoid cell lines[83]. L72’s
clinical studies showed injections caused regression in melanoma tumor cells,
except for patients who had tumors with low antigenicity. After that, no further
studies were reported.
ch14.18 is the chimeric form of m14.G2a, and hu14.18 is the human form. The
names were derived from the original mouse isotype 14.18 IgG3. Phase 1 studies
concluded the safety of both forms, with a warning about severe pain during administration and other possible side effects. Phase 3 studies showed that combining
ch14.18with GM-CSF and interleukin-2 can greatly increase the two-year survival
rate of patients with high-risk neuroblastoma in comparison to the standard therapy options.
Murine 3F8 was also humanized (hu3F8) through grafting on the CDR, and it is
currently in Phase 1 trials. Initial test results show a reduction in the production of
HAHA and complement activation in comparison to murine 3F8[83].
7.7.6 Naxitamab asa Potential Alternative forHigh-Risk Patients
In 2020, the ongoing research efforts to reduce the toxicity and development of
human anti-mouse antibodies (HAMA) in anti-GD2 antibodies like dinutuximab
were a success, and naxitamab, marketed as Danyelza®, was approved by the
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
FDA[90]. Naxitamab is a humanized anti-GD2monoclonal antibody developed by
Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics Inc.[41, 91].
Structurally speaking, naxitamab is very similar to dinutuximab, except some
mouse components have been substituted with human ones[64]. Naxitamab is a
treatment for high-risk neuroblastoma, osteosarcoma, and many other GD2positive cancers. This drug is injected intravenously in combination with GM-CSF
to treat patients with relapsed or refractory high-risk neuroblastoma in the bone or
bone marrow[41, 92]. This drug regimen is an improvement over Unituxin because
it has a shorter infusion time (naxitamab infuses in 30–60
hours needed for Unituxin), and it can be used in a greater age range of
10–20
minutes compared to the
patients, from 1-year-olds to adults[41, 91]. As mentioned above, Unituxin is too
risky for most adults to use because of the high probability of side effects. Also,
because of the toxicity profiles, dinutuximab is for inpatient administration only,
while naxitamab allows for outpatient administration and a better quality of life
−1
during treatment[41]. Naxitamab’s recommended dosage is 3 mg kg
day−1[41].
This treatment cycle is administered on days 1, 3, and 5 of a four-week-long treatment. The treatment cycle is repeated every four weeks until a complete or partial
response is noted[41, 91, 92]. Once a response is noted, the studies recommend at
least five more treatment cycles. However, be warned that this treatment still has
risks because it may cause severe infusion-related reactions and neurotoxicity[41].
During testing, the drug showed promising binding via surface plasmon resonance
to GD2 coated onto CM5 chips. Naxitamab had a k
1.03E, a K
value of 11 nM, and low reactivity with gangliosides other than
D
GD2[91]. In fact, naxitamab’s affinity for GD2 is 10
value of 9.19, a k
on
times higher than dinutuxi-
value of
off
mab’s affinity [41]. These results, along with the drug’s cytotoxicity against the
LAN-1neuroblastoma cell line with an EC
of 5.1 μg ml−1, allow naxitamab to be
50
a treatment option for patients with high-risk neuroblastoma[91]. When naxitamab is used as a treatment in conjunction with GM-CSF, the three-year EFS is
74.3% and the OS is 91.6%, which is an increase in survival rates compared to
dinutuximab[41].
213
7.7.7 Chimeric Antigen Receptors (CARs) Targeting GD2
Therefore, alternative cancer cell targets are necessary for treatment options. This
idea led to the discovery of T-cell-independent carbohydrate differentiation antigens, such as GD2, GD3, O-acetylated GD2 and GD3, and polysialic acid (PSA)[68].
mAbs can be used as chimeric antigen receptors (CARs) or bispecific antibodies,
such as anti-GD2 and anti-CD3, to allow polyclonal T cells to target tumors. CARs
are single-chain Fv fragments that can fuse through the transmembrane domain of
T-cell-activating motifs, such as CD3ζ and CD28 or 41BB, to allow the T cells to
target a specific protein[68]. All of these possible neuroblastoma-killing pathways
are illustrated in Figure7.4. There are several CARs that have gone through clinical
trials; here is an example of an anti-GD2 CAR that utilized an scFv based on
7 Carbohydrate-Specific Monoclonal Antibody Therapeutics
CMC
(anti-GD2 and anti-CD3)
n)
214
Phagocytosis
Macrophage
Anti-GD2 antibody
(e.g. 3F8 or ch14.18)
Bispecific antibody
KEY
GD2 Peptide
Other targets
(e.g. GD3, PSA, or ALK)
CAR
Immune
inactivators
Fc receptor
Neuroblastoma
Rare or
absent
C1q
MAC
HLA
T cell
Granulocyte-ADCC
Activation
Granulocyte
Cytotoxin
(e.g. granzyme or perfori
NK cell
NK-ADCC
Dendritic cell
Figure7.4 Illustration of potential immune responses to neuroblastoma tumor cells.
Source: Adapted from Cheyung and Dyer[68].
humanized murine antibody KM8138 that is fused to CD28 [93]. This trial took
children with relapsed or refractory neuroblastoma; out of 34 patients, only 15%
reported a partial response. In this study, two patients showed significant tumor
regression; one had two large tumors and the other patient had one retroperitoneal
tumor. Both patients had greater than 90% regression after two months of CAR
T-cell therapy[94]. There are drawbacks to CARs; in a different phase 1 clinical trial,
anti-GD2 CAR was administered to 11 patients with relapsed or refractory neuroblastoma. The patients were treated with either anti-GD2 CAR T cells alone or in
conjunction with lymphodepleting chemotherapy. This trial saw minimal activity
with no measurable responses in all patients. CAR T cells aggregated and caused
tonic signaling of 14g2a anti-GD2 scFv; this led to T-cell exhaustion and limited
antitumor efficacy[95].
7.8 Summary
Overall, carbohydrate-specific mAbs that target carbohydrate antigens have proven
to be effective as therapies against cancer, and what waits in the wings is further
development against bacterial infections and viruses. Unituxin and naxitamab have
paved the path for using immunotherapeutics against carbohydrates a reality. The
research community will need to take advantage of carbohydrate antigens further to
develop other important therapies in the quest to combat disease more effectively.
List ofAbbreviations
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
tumor-associated carbohydrate antigens TACAs
antibody-dependent cell-mediated cytotoxicity
complement-dependent cytotoxicity
monoclonal antibodies
natural killer
gra
nulocyte–macrophage colony-stimulating
factor
interleukin 2
isotretinoin
Biopharmaceutical Development Program
United Therapeutics Corporation
Food and Drug Administration
European Commission
event-free survival
overall survival
human anti-mouse antibodies
human leukocyte antigen
cytotoxic T lymphocyte
FAS ligand
polysialic acid
NK
cell-mediated antibody-dependent
cell-mediated cytotoxicity
granulocyte-mediated ADCC
complement-mediated cytotoxicity
membrane attack complex
chimeric antigen receptors
single-chain Fv fragments
anaplastic lymphoma receptor tyrosine kinase ALK
central nervous system CNS
lactosylceramide LacCer
asialo-GM2 GA2
cerebrospinal fluid CSF
extracellular matrix ECM
focal adhesion kinase FAK
m3F8 murine IgG3
14G2a murine IgG2a
β-glucan BG
Epstein–Barr virus EBV
humanized m3F8 hu3F8
complementarity-determining region CDR
NK
GM-CSF
IL-2
13-cis-retinoic acid- RA
OS
FASL
PSA
mAbs
EC
EFS
HLA
CTL
MAC
CARs
scFvs
CDC
UTC
FDA
HAMA
NK-ADCC
granulocyte ADCC
CMC
ADCC
BDP
215
7 Carbohydrate-Specific Monoclonal Antibody Therapeutics
216
References
1 Harris, R.J. (2005). Heterogeneity of recombinant antibodies: linking structure to
function. Developmental Biology 122: 117–127.
2 Xia, L., Schrump, D.S., and Gildersleeve, J.C. (2016). Whole-cell cancer vaccines
induce large antibody responses to carbohydrates and glycoproteins. Cell Chemical
Biology 23 (12): 1515.
3 Sterner, E., Flanagan, N., and Gildersleeve, J.C. (2016). Perspectives on anti-glycan
antibodies gleaned from development of a community resource database. ACS
Chemical Biology 11 (7): 1773.
4 Pier, G.B., Lyczak, J.B., Wetzler, L.M., and Ruebush, M.J. (2004). Immunology,
infection, and immunity. ASM 196–197.
5 Milholland, B., Dong, X., Zhang, L. etal. (2017). Differences between germline and
somatic mutation rates in humans and mice. Nature Communications 8: 15183.
6 Correia, I.R. (2010). Stability of IgG isotypes in serum. MAbs 2: 221–232.
7 Muhammed, Y. (2020). The best IgG subclass for the development of therapeutics
monoclonal antibodies drugs and their commercial production: a review.
Immunome Research 16: 173.
8 Ochoa, M.C., Minute, L., Rodriguez, I. etal. (2017). Antibody-dependent cell
cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunology
and Cell Biology 95: 347–355.
9 Irani, V., Guy, A.J., Andrew, D. etal. (2015). Molecular properties of human IgG
subclasses and their implications for designing therapeutic monoclonal antibodies
against infectious diseases. Molecular Immunology 67: 171–182.
10 Nimmerjahn, F. and Ravetch, J.V. (2005). Divergent immunoglobulin g subclass
activity through selective Fc receptor binding. Science 310: 1510–1512.
11 Carter, P.J. (2006). Potent antibody therapeutics by design. Nature Reviews
Immunology 65: 343–357.
12 Vidarsson, G., Dekkers, G., and Rispens, T. (2014). IgG subclasses and allotypes:
from structure to effector functions. Frontiers in Immunology 5: 520.
13 Strohl, W.R. and Strohl, L.M. (2012). Therapeutic Antibody Engineering, 197–223.
Woodhead Publishing.
14 Wibroe, P.P., Helvig, S.Y., and Moein Moghimi, S. (2014). The role of complement
in antibody therapy for infectious diseases. Microbiology Spectrum 2: 63–74.
15 Klimovich, V.B. (2011). IgM and its receptors: structural and functional aspects.
Biochemistry (Moscow) 76: 534–549.
16 Sharp, T.H., Boyle, A.L., Diebolder, C.A. etal. (2019). Insights into IgM-mediated
complement activation based on in situ structures of IgM-C1-C4b. Proceedings of
the National Academy of Sciences 24: 11900–11905.
17 Shibuya, A., Sakamoto, N., Shimizu, Y. etal. (2000). Fc alpha/mu receptor mediates
endocytosis of IgM-coated microbes. Nature Immunology 1: 441–446.
18 Weinstein, J.R., Quan, Y., Hanson, J.F. etal. (2015). IgM-dependent phagocytosis in
microglia is mediated by complement receptor 3, Not Fc alpha/mu receptor.
Journal of Immunology 195: 5309–5317.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
19 Line, B.R., Breyer, R.J., McElvany, K.D. etal. (2004). Evaluation of human anti-
mouse antibody response in normal volunteers following repeated injections of
fanolesomab (NeutroSpec), a murine anti-CD15 IgM monoclonal antibody for
imaging infection. Nuclear Medicine Communications 25: 807–811.
20 Liedtke, M., Twist, C.J., Medeiros, B.C. etal. (2012). Phase I trial of a novel human
monoclonal antibody mAb216in patients with relapsed or refractory B-cell acute
lymphoblastic leukemia. Haematologica 97: 30–37.
21 Bhat, N.M., Bieber, M.M., Chapman, C.J. etal. (1993). Human anti-lipid A
monoclonal antibodies bind to human B cells and the i antigen on cord red blood
cells. Journal of Immunology 151: 5011–5021.
22 Bird, R.E., Hardman, K.D., Jacobson, J.W. etal. (1988). Single-chain antigen-
binding proteins. Science 242: 423–426.
23 Huston, J.S., Levinson, D., Mudgett-Hunter, M. etal. (1988). Protein engineering of
antibody binding sites: recovery of specific activity in an anti-digoxin single-chain
Fv analogue produced in Escherichia coli. Proceedings of the National Academy of
Sciences of the United States of America 85: 5879–5883.
24 Spadiut, O., Capone, S., Krainer, F. etal. (2014). Microbials for the production of
monoclonal antibodies and antibody fragments. Trends in Biotechnology 32: 54–60.
25 Yokota, T., Milenic, D.E., Whitlow, M., and Schlom, J. (1992). Rapid tumor
penetration of a single-chain Fv and comparison with other immunoglobulin
forms. Cancer Research 12: 3402–3408.
26 Ahmadzadeh, V. (2014). Antibody humanization methods for development of
therapeutic applications. Monoclonal Antibodies in Immunodiagnosis
Immunotherapy 33: 67–73.
27 Dondelinger, M. (2018). Understanding the significance and implications of
antibody numbering and antigen-binding surface/residue definition. Frontiers in
Immunology 9: 2278.
28 Lu, R.M., Hwang, Y.C., Liu, I.J. etal. (2020). Development of therapeutic antibodies
for the treatment of diseases. Journal of Biomedical Science 27: 1.
29 Almagro, J.C. and Fransson, J. (2008). Humanization of antibodies. Frontiers in
Bioscience: a Journal and Virtual Library 13: 1619–1633.
30 Harding, F.A., Stickler, M.M., Razo, J., and DuBridge, R.B. (2010). The
immunogenicity of humanized and fully human antibodies: residual
immunogenicity resides in the CDR regions. MAbs 3: 256–265.
31 Ducancel, F. and Muller, B.H. (2012). Molecular engineering of antibodies for
therapeutic and diagnostic purposes. MAbs 4: 445–457.
32 Hansel, T.T., Kropshofer, H., Singer, T. etal. (2010). The safety and side effects of
monoclonal antibodies. Nature Reviews Drug Discovery 9: 325.
33 Waldmann, H. (2019). Human monoclonal antibodies: the benefits of
humanization. Methods in Molecular Biology 1904: 1–10.
34 Safdari, Y. (2013). Antibody humanization methods–a review and update.
Biotechnology & Genetic Engineering Reviews 29: 175–186.
35 Kashmiri, S. (2005). SDR grafting–a new approach to antibody humanization.
Methods 36: 25–34.
217
7 Carbohydrate-Specific Monoclonal Antibody Therapeutics
218
36 Bruggemann, M., Caskey, H.M., Teale, C. etal. (1989). A repertoire of monoclonal
antibodies with human heavy chains from transgenic mice. Proceedings of the
National Academy of Sciences 86: 6709–6713.
37 Choi, T.K., Hollenbach, P.W., Pearson, B.E. etal. (1993). Transgenic mice
containing a human heavy chain immunoglobulin gene fragment cloned in a yeast
artificial chromosome. Nature Genetics 4: 117–123.
38 Davies, N.P., Rosewell, I.R., Richardson, J.C. etal. (1993). Creation of mice
expressing human antibody light chains by introduction of a yeast artificial
chromosome containing the core region of the human immunoglobulin kappa
locus. Biotechnology 11: 911–914.
39 Osborn, M.J., Ma, B., Avis, S. etal. (2013). High-affinity IgG antibodies develop
naturally in Ig-knockout rats carrying germline human IgH/Igkappa/Iglambda loci
bearing the rat CH region. Journal of Immunology 190: 1481–1490.
40 Lee, E.C., Liang, Q., Ali, H. etal. (2014). Complete humanization of the mouse
immunoglobulin loci enables efficient therapeutic antibody discovery. Nature
Biotechnology 32: 356–363.
41 Mora, J., Castañeda, A., Gorostegui, M. etal. (2021). Naxitamab combined with
granulocyte-macrophage colony-stimulating factor as consolidation for high-risk
neuroblastoma patients in complete remission. Pediatric Blood & Cancer 68: e29121.
42 Oyelaran, O. and Gildersleeve, J.C. (2007). Application of carbohydrate array
technology to antigen discovery and vaccine development. Expert Review of
Vaccines (6): 957–969.
43 Trabbic, K.R., Kleski, K.A., Shi, M., and Andreana, P. (2018). Production of a mouse
monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer
antigen resulting in invivo and invitro tumor killing. Cancer Immunology,
Immunotherapy 67: 1437–1447.
44 DiMasi, J. etal. (2016). Innovation in the pharmaceutical industry: new estimates
of R&D costs. Journal of Health Economics 47: 20–33.
45 Suvarna, V. (2010). Phase IV of drug development. Perspectives in Clinical Research
2: 57–60.
46 Yu, A.L., Hung, J.T., Ho, M.Y., and Yu, J. (2016). Alterations of glycosphingolipids
in embryonic stem cell differentiation and development of glycan-targeting cancer
immunotherapy. Stem Cells and Development 25: 1532–1548.
47 Yu, J. (2020). Targeting glycosphingolipids for cancer immunotherapy. FEBS Letters
594: 3602–3618.
48 Zhang, S. (1997). Selection of tumor antigens as targets for immune attack using
immunohistochemistry: I. Focus on gangliosides. International Journal of Cancer
73: 42–49.
49 Zhang, S. (1998). Expression of potential target antigens for immunotherapy on
primary and metastatic prostate cancers. Clinical Cancer Research 4: 295–302.
50 Ruggiero, F.M., Rodríguez-Walker, M., and Daniotti, J.L. (2020). Exploiting the
internalization feature of an antibody against the glycosphingolipid SSEA-4 to
deliver immunotoxins in breast cancer cells. Immunology and Cell Biology 98:
187–202.
References
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
51 Yang, M.C., Shia, C.S., Li, W.F. etal. (2021). Preclinical Studies of OBI-999: a novel
globo H-targeting antibody-drug conjugate. Molecular Cancer Therapeutics 20:
1121–1132.
52 Bennett, E.P., Mandel, U., Clausen, H. etal. (2012). Control of mucin-type
O-glycosylation: a classificationof the polypeptide GalNAc-transferase gene family.
Glycobiology 22: 736–756.
53 Lavrsen, K., Madsen, C.B., Rasch, M.G. etal. (2013). Aberrantly glycosylated MUC1
is expressed on the surface of breast cancer cells and a target for antibodydependent cell-mediatedcytotoxicity. Glycoconjugate Journal 30: 227–236.
54 Colcher, D., Hand, P.H., Nuti, M., and Schlom, J. (1981). A spectrum of monoclonal
antibodies reactive with human mammary tumor cells. Proceedings of the National
Academy of Sciences of the United States of America 78: 3199–3203.
55 Cervoni, G.E., Cheng, J.J., Stackhouse, K.A. etal. (2020). O-glycan recognition and
function in mice and human cancers. The Biochemical Journal 477: 1541–1564.
56 Munkley, J. (2016). The role of sialyl-Tn in cancer. International Journal of
Molecular Sciences 17: 275.
57 Muraro, R. (1988). Generation and characterization of B72.3 second generation
monoclonal antibodies reactive with the tumor-associatedglycoprotein 72 antigen.
Cancer Research 48: 4588–4596.
58 Gong, Y., Klein Wolterink, R.G.J., Gulaia, V. etal. (2021). Defucosylation of
tumor-specific humanized anti-MUC1monoclonal antibody enhances NK
cell-mediated anti-tumor cell cytotoxicity. Cancers 13: 2579.
59 Fiedler, W. (2016). A phase I study of PankoMab-GEX, a humanised glyco-
optimised monoclonal antibody to a novel tumour-specific MUC1glycopeptide
epitope in patients with advanced carcinomas. European Journal of Cancer
63: 55–63.
60 Póka, R. (2017). LBA41A double-blind, placebo-controlled, randomized, phase 2
study to evaluate the efficacy and safety of switchmaintenance therapy with the
anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with
recurrent epithelial ovarian carcinoma. Annals of Oncology 28 (Suppl. 5): v626.
Discovery and vaccine development. Expert Review of Vaccines 2007, (6) 957–969.
61 Garralda, E. (2021). Activity results of the GATTO study, a phase Ib study
combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR
tomuzotuximab or panitumumab in patients with refractory solid tumors. Journal
of Clinical Oncology 39: 2522.
62 McGinty, L. and Kolesar, J. (2017). Dinutuximab for maintenance therapy in
pediatric neuroblastoma. American Journal of Health-System Pharmacy 74 (8): 563.
63 Nallasamy, P., Chava, S., Verma, S.S. etal. (2018). PD-L1, inflammation, non-coding
RNAs, and neuroblastoma: Immuno-oncology perspective. Seminars in Cancer
Biology (52): 53.
64 Kowalczyk, A., Gil, M., Horwacik, I. etal. (2009). The GD2-specific 14G2a
monoclonal antibody induces apoptosis and enhances cytotoxicity of
chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Letters 281
(2): 171.
219
7 Carbohydrate-Specific Monoclonal Antibody Therapeutics
220
65 Greenwood, K.L. and Foster, J.H. (2018). The safety of dinutuximab for the
treatment of pediatric patients with high-risk neuroblastoma. Expert Opinion on
Drug Safety 17 (12): 1257.
66 Ploessl, C., Pan, A., Maples, K.T., and Lowe, D.K. (2016). Dinutuximab: an
anti-GD2monoclonal antibody for high-risk neuroblastoma. The Annals of
Pharmacotherapy 50 (5): 416.
67 Gur, H., Ozen, F., Can Saylan, C., and Atasever-Arslan, B. (2017). Dinutuximab in
the treatment of high-risk neuroblastoma in children. Clinical Medicine Insights:
Therapeutics 9.
68 Cheung, N.K. and Dyer, M.A. (2013). Neuroblastoma: developmental biology,
cancer genomics and immunotherapy. Nature Reviews. Cancer 13 (6): 397.
69 Yang, R.K. and Sondel, P.M. (2010). Anti-GD2 strategy in the treatment of
neuroblastoma. Drugs of the Future 35 (8): 665.
70 Marachelian, A., Desai, A., Balis, F. etal. (2016). Comparative pharmacokinetics,
safety, and tolerability of two sources of ch14.18in pediatric patients with high-risk
neuroblastoma following myeloablative therapy. Cancer Chemotherapy and
Pharmacology 77 (2): 405.
71 Yu, A.L., Eskenazi, A., Strother, D., and Castleberry, R. (2001). A pilot study of
anti-idiotype monoclonal antibody as tumor vaccine in patients with high-risk
neuroblastoma. Proc Am Soc. Clinical Oncology 20: 1470.
72 Boune, S., Hu, P., Epstein, A.L., and Khawli, L.A. (2020). Principles of N-linked
glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional
considerations. Antibodies (Basel, Switzerland) 9 (2): 22.
73 Almagro, J.C., Daniels-Wells, T.R., Perez-Tapia, S.M., and Penichet, M.L. (2017).
Progress and challenges in the design and clinical development of antibodies for
cancer therapy. Frontiers in Immunology 8: 1751.
74 Dinutuximab (Unituxin™). National Cancer Institute Technology Transfer Center
(2016). https://techtransfer.cancer.gov/aboutttc/successstories/
dinutuximabunituxin
75 Lu, R.M., Hwang, Y.C., Liu, I.J. etal. (2020). Development of therapeutic antibodies
for the treatment of diseases. Journal of Biomedical Science 27 (1): 1.
76 Reichert, J.M. (2016). Antibodies to watch in 2016. MAbs 8 (2): 197.
77 Barker, E., Mueller, B.M., Handgretinger, R. etal. (1991). Effect of a chimeric
anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma
cells. Cancer Research 51 (1): 144.
78 Hoy, S.M. (2016). Dinutuximab: a review in high-risk neuroblastoma. Targeted
Oncology 11 (2): 247.
79 Keegan, P. (2015). Unituxin injection/dinutuximab. In Division Directory Summary
Review, Corporation, U. T., Ed. STN BL 125516: Center for Drug Evaluation and
Research, 3713106.
80 Zhang, P., Woen, S., Wang, T. etal. (2016). Challenges of glycosylation analysis and
control: an integrated approach to producing optimal and consistent therapeutic
drugs. Drug Discovery Today 21 (5): 740.
81 Hristodorov, D., Fischer, R., and Linden, L. (2013). With or without sugar?
(A)glycosylation of therapeutic antibodies. Molecular Biotechnology 54 (3): 1056.
Соседние файлы в папке Библиотека им академика М.И. Перельмана